Skip to main content
  • Meeting abstract
  • Open access
  • Published:

In-hospital experience with insulin degludec (IDeg)


Glycemic control is critical for in-patients and dysglycemia is associated with worse prognosis and higher mortality. Insulin therapy is considered the best treatment on this scenario and basal insulin analogues, such as insulin glargine (IGlar) and IDeg, could be useful options, however there are no studies comparing IGlar and IDeg evaluating glucose variability (GV) in hospitalized patients, neither the transition between them.


To present a case series describing the efficacy and safety of IDeg in-patientes with diabetes using GV and rate of hypoglycemia when compared with IGlar.

Materials and methods

Retrospective analysis of blood glucose obtained with point-of-care testing of 10 diabetic patients admitted at Bandeirantes Hospital, Sao Paulo, between October 2014 and April 2015, previously treated with IGlar for a minimum of 7 days and switched to IDeg for at least 7 days more during hospitalization. Parameters studied included GV, standard deviation (SD), coefficient of variation (CV) and mean glucose levels, obtained from software PXP Abbott. Hypoglycemia was defined as blood glucose (BG) <70mg/dL and it was severe if BG <40mg/dL. Basal insulin dose was compared on the last day of both, after achievement of steady state.


3/10 patients had type 1 diabetes mellitus (T1D) for over 10 yrs., previous treatment with insulin therapy in a basal-bolus regimen. Average age was 46 yrs. and mean HbA1c was 9% and no benefit could be noticed. 7/10 patients had type 2 diabetes mellitus (T2D), with duration of >10 yrs., the majority had previous insulin treatment. Mean age was 70 yrs. and mean HbA1c was 9,7%. All T2D patients maintained CV, and 57% had a reduction in SD, improving GV. Basal insulin dose with IDeg was lower at discharge as compared to IGlar in T2D. Severe hypoglycemia events were diminished after switching (see Figure 1).

Figure 1
figure 1

Summary of results


In this report, GV was lower in T2D patients treated with IDeg as compared to IGlar, although the same could not be seen in T1D, perhaps due to the small number of patients included. More studies in this population are needed to confirm this hypothesis and continuous glucose monitoring should be preferred. IDeg proved to be a safe and effective alternative at hospital and might improve GV. This would be better due to its predictability of effect and low rate of hypoglycemia, important among hospitalized patients.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Maria Fernanda Ozorio de Almeida.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bulisani, M.G.P., de Almeida, M.F.O., Abdon, C.M. et al. In-hospital experience with insulin degludec (IDeg). Diabetol Metab Syndr 7 (Suppl 1), A90 (2015).

Download citation

  • Published:

  • DOI: